{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:57:44Z","timestamp":1791557864358,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00406-026-02249-3","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:46:46Z","timestamp":1777351606000},"page":"2789-2798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"276","author":[{"given":"Antonio","family":"Di Francesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfelice","family":"Cutrufelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zambuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Concerto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Mineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Catalfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Salvina","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"2249_CR1","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2(3):e94","journal-title":"Transl Psychiatry"},{"key":"2249_CR2","doi-asserted-by":"publisher","first-page":"614811","DOI":"10.3389\/fphar.2021.614811","volume":"12","author":"FM Leweke","year":"2021","unstructured":"Leweke FM et al (2021) Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Front Pharmacol 12:614811","journal-title":"Front Pharmacol"},{"issue":"10","key":"2249_CR3","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1038\/tp.2016.195","volume":"6","author":"P Seeman","year":"2016","unstructured":"Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 6(10):e920","journal-title":"Transl Psychiatry"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S et al (2019) Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology 74:282\u2013298","journal-title":"Neurotoxicology"},{"issue":"8","key":"2249_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB et al (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30(8):1037\u20131043","journal-title":"Neurochem Res"},{"key":"2249_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bcp.2018.08.046","volume":"157","author":"G Navarro","year":"2018","unstructured":"Navarro G et al (2018) Cannabidiol skews biased agonism at cannabinoid CB(1) and CB(2) receptors with smaller effect in CB(1)-CB(2) heteroreceptor complexes. Biochem Pharmacol 157:148\u2013158","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"2249_CR7","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB et al (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172(20):4790\u20134805","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2249_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/7268","volume":"2","author":"A Giuffrida","year":"1999","unstructured":"Giuffrida A et al (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2(4):358\u2013363","journal-title":"Nat Neurosci"},{"key":"2249_CR9","doi-asserted-by":"crossref","unstructured":"Couttas TA et al (2024) Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers. BMJ Ment Health 27(1)","DOI":"10.1136\/bmjment-2024-301027"},{"key":"2249_CR10","doi-asserted-by":"publisher","first-page":"176821","DOI":"10.1016\/j.ejphar.2024.176821","volume":"979","author":"JS Denis Volker","year":"2024","unstructured":"Denis Volker JS, Miclutia IV, Vinasi RC (2024) Investigating Cannabidiol\u2019s potential as a supplementary treatment for schizophrenia: A narrative review. Eur J Pharmacol 979:176821","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"2249_CR11","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S et al (2018) Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 78(17):1791\u20131804","journal-title":"Drugs"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"116049","DOI":"10.1016\/j.psychres.2024.116049","volume":"339","author":"K Han","year":"2024","unstructured":"Han K et al (2024) Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res 339:116049","journal-title":"Psychiatry Res"},{"key":"2249_CR13","doi-asserted-by":"publisher","first-page":"113246","DOI":"10.1016\/j.psychres.2020.113246","volume":"291","author":"E Kopelli","year":"2020","unstructured":"Kopelli E et al (2020) The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. Psychiatry Res 291:113246","journal-title":"Psychiatry Res"},{"key":"2249_CR14","doi-asserted-by":"publisher","first-page":"136064","DOI":"10.1016\/j.neulet.2021.136064","volume":"759","author":"A Seillier","year":"2021","unstructured":"Seillier A (2021) The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 759:136064","journal-title":"Neurosci Lett"},{"issue":"7","key":"2249_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"11","key":"2249_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002","journal-title":"BMJ"},{"issue":"3","key":"2249_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175(3):225\u2013231","journal-title":"Am J Psychiatry"},{"issue":"7","key":"2249_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL et al (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235(7):1923\u20131932","journal-title":"Psychopharmacology"},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"736822","DOI":"10.3389\/fpsyt.2021.736822","volume":"12","author":"P Kock","year":"2021","unstructured":"Kock P et al (2021) Cannabidiol cigarettes as adjunctive treatment for psychotic disorders - a randomized, open-label pilot-study. Front Psychiatry 12:736822","journal-title":"Front Psychiatry"},{"key":"2249_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpsychires.2023.05.019","volume":"163","author":"R van Boxel","year":"2023","unstructured":"van Boxel R et al (2023) The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder. J Psychiatr Res 163:93\u2013101","journal-title":"J Psychiatr Res"},{"issue":"4","key":"2249_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF02244012","volume":"100","author":"FS Guimaraes","year":"1990","unstructured":"Guimaraes FS et al (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100(4):558\u2013559","journal-title":"Psychopharmacology"},{"key":"2249_CR23","doi-asserted-by":"publisher","first-page":"104749","DOI":"10.1016\/j.phrs.2020.104749","volume":"156","author":"N Rodrigues da Silva","year":"2020","unstructured":"Rodrigues da Silva N et al (2020) Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacol Res 156:104749","journal-title":"Pharmacol Res"},{"key":"2249_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fphar.2013.00169","volume":"4","author":"P Sanchez-Blazquez","year":"2014","unstructured":"Sanchez-Blazquez P, Rodriguez-Munoz M, Garzon J (2014) The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 4:169","journal-title":"Front Pharmacol"},{"issue":"1607","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC et al (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367(1607):3364\u20133378","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"2249_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","volume":"39","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW et al (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39(4):421\u2013429","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"2249_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM et al (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825\u2013836","journal-title":"Neurotherapeutics"},{"key":"2249_CR28","doi-asserted-by":"publisher","first-page":"204512531988191","DOI":"10.1177\/2045125319881916","volume":"9","author":"C Davies","year":"2019","unstructured":"Davies C, Bhattacharyya S (2019) Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 9:2045125319881916","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"2249_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00213-021-05905-9","volume":"239","author":"E Chesney","year":"2022","unstructured":"Chesney E, Oliver D, McGuire P (2022) Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology 239(5):1179\u20131190","journal-title":"Psychopharmacology"},{"issue":"4","key":"2249_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","volume":"51","author":"A O\u2019Neill","year":"2021","unstructured":"O\u2019Neill A et al (2021) Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med 51(4):596\u2013606","journal-title":"Psychol Med"},{"key":"2249_CR31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA et al (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365","journal-title":"Front Pharmacol"},{"issue":"1","key":"2249_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2(1):139\u2013154","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02249-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:02:15Z","timestamp":1788015735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02249-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02249-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Leucht has received honoraria for advising, consulting, and for lectures and\/or for educational from Angelini, Apsen, Boehringer Ingelheim, Eisai, Ekademia, GedeonRichter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Mitsubishi, Neurotorium, Otsuka, Novo Nordisk, Recordati, Rovi, and Teva.Other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors utilized OpenAI\u2019s ChatGPT-4 mini to enhance readability and grammar. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}